These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 5121458)

  • 21. [ECG and morphologic changes in animal myocardium during intravenous administration of amphotericin B].
    Dumova AM; Spasskaia MG
    Antibiotiki; 1973 Jul; 18(7):650-5. PubMed ID: 4773830
    [No Abstract]   [Full Text] [Related]  

  • 22. [Safety of long-term administration of conventional amphotericin B in oncology patients].
    Doubek M; Mayer J; Horký D
    Cas Lek Cesk; 2002 Mar; 141(5):156-9. PubMed ID: 11998223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Histopathological changes in dog kidneys following administration of lienomycin].
    Belova IP
    Antibiotiki; 1973 Jul; 18(7):645-50. PubMed ID: 4773829
    [No Abstract]   [Full Text] [Related]  

  • 24. [Safety of liposomal amphotericin B in patients with high risk of nephrotoxicity].
    González E; Rada MA; Lumbreras C; Ramos JT; Aguado JM
    Enferm Infecc Microbiol Clin; 2000 Apr; 18(4):162-4. PubMed ID: 10932392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicity of amphotericins on chronic administration to mongrel dogs.
    Hoeprich PD; Huston AC; Wolfe BM
    Diagn Microbiol Infect Dis; 1985 Jan; 3(1):47-58. PubMed ID: 3967472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection from amphotericin B-induced lipid peroxidation in rats by fructose-1,6-diphosphate.
    Rao MR; Olinde KD; Markov AK
    Res Commun Mol Pathol Pharmacol; 1997 Feb; 95(2):217-20. PubMed ID: 9090757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of amphotericin B and cholera toxin on intestinal transport in the rat. An in vivo model for the effects of dihydroxy bile acids and fatty acids on intestinal transport.
    Ammon HV; Walter LG; Loeffler RF
    J Lab Clin Med; 1983 Oct; 102(4):509-21. PubMed ID: 6413628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments.
    Lincopan N; Mamizuka EM; Carmona-Ribeiro AM
    J Antimicrob Chemother; 2005 May; 55(5):727-34. PubMed ID: 15761070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
    Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
    Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
    Rieger CT; Dittmer M; Ostermann H
    Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacology of amphotericin B.
    Pyle RL
    J Am Vet Med Assoc; 1981 Jul; 179(1):83-4. PubMed ID: 7251466
    [No Abstract]   [Full Text] [Related]  

  • 32. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Amphotericin B: its characteristics and means of application].
    Plakhotnaia GA
    Antibiotiki; 1982 Nov; 27(11):859-70. PubMed ID: 6758683
    [No Abstract]   [Full Text] [Related]  

  • 34. Sodium chloride treatment of amphotericin B nephrotoxicity. Standard of care?
    Anderson CM
    West J Med; 1995 Apr; 162(4):313-7. PubMed ID: 7747495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms and management of amphotericin B-induced nephrotoxicity.
    Miano-Mason TM
    Cancer Pract; 1997; 5(3):176-81. PubMed ID: 9171554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amphotericin B-related nephrotoxicity has an economic impact on hospitals and health systems.
    Prendergrast MM; Tong KB
    Clin Infect Dis; 2003 Nov; 37(10):1396; author reply 1396-7. PubMed ID: 14583877
    [No Abstract]   [Full Text] [Related]  

  • 37. Liposomal amphotericin B therapy in disseminated histoplasmosis.
    Harten P; Baron Y; Euler HH
    Arch Intern Med; 1995 Jul; 155(14):1556. PubMed ID: 7605161
    [No Abstract]   [Full Text] [Related]  

  • 38. Assessment of nephrotoxicity of high-cumulative dose of liposomal amphotericin B in a pediatric patient who underwent allogeneic bone marrow transplantation.
    Cesaro S; Zignol M; Burlina AB; Tridello G; Visintin G; Messina C
    Pediatr Transplant; 2006 Mar; 10(2):255-8. PubMed ID: 16573618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicity of an effective amphotericin B formulation at high cationic lipid to drug molar ratio.
    Lincopan N; Borelli P; Fock R; Mamizuka EM; Carmona-Ribeiro AM
    Exp Toxicol Pathol; 2006 Nov; 58(2-3):175-83. PubMed ID: 16982179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amphotericin B deoxycholate administered by continuous infusion: does the dosage make a difference?
    Hiemenz JW
    Clin Infect Dis; 2003 Apr; 36(8):952-3. PubMed ID: 12684905
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.